ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Hydroxychloroquine"

  • Abstract Number: 322 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population

    Leanna Wise1, Stavros Savvas 2 and Elizabeth Ortiz 2, 1LAC+USC/Keck Medicine of USC, Los Angeles, CA, 2LAC+USC/Keck Medicine of USC, Los Angeles

    Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
  • Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting

    A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity

    Eric Liu1 and Andras Perl 2, 1SUNY Upstate University Medical Center, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
  • Abstract Number: 896 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

    April Jorge1, Na Lu 2, Hyon K. Choi 1, John Esdaile 3, Diane Lacaille 4 and J. Antonio Avina-Zubieta 5, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hosptial, Boston, MA, 3Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, 4Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, 5Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…
  • Abstract Number: 2581 • 2019 ACR/ARP Annual Meeting

    Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus

    Nicolle Medina-Cintrón1, Ileana Vázquez-Otero 1, Mariangelí Arroyo-Ávila 1, Lorena González-Sepúlveda 1 and Luis Vilá 1, 1University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

    Background/Purpose: Hydroxychloroquine (HCQ) is one of the main drugs used for the treatment of systemic lupus erythematosus (SLE). Nonetheless, HCQ-induced retinal toxicity remains a major…
  • Abstract Number: 1130 • 2019 ACR/ARP Annual Meeting

    The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine

    Abdulrahman Alrashid1, Millicent Anne Stone 2, Nigel Davies 2 and David D'Cruz 3, 1King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia, 2Guy's and St Thomas Foundation Trust, London, United Kingdom, 3The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom

    Background/Purpose: Background: Hydroxychloroquine (HCQ) is widely used in treatment of autoimmune rhuematological diseases. In particular, systemic lupus erythermatosus where it proved to prevent disease flare, reduce…
  • Abstract Number: 2829 • 2019 ACR/ARP Annual Meeting

    Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk

    Shivani Garg1, Betty Chewning 2, Karen Hansen 3, Beth Martin 2 and Christie Bartels 1, 1University of Wisconsin School of Medicine and Public Health, Madison, WI, 2UW - School of Pharmacy, Madison, Madison, 3UW Madison, Madison

    Background/Purpose: Up to 83% of patients with SLE are nonadherent to hydroxychloroquine (HCQ) which results in a 36% higher risk of renal failure, and 8-fold…
  • Abstract Number: 1748 • 2019 ACR/ARP Annual Meeting

    Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood

    Sara Patrizi1, Douglas Stram 2, Miranda Weintraub 3 and Alexandra Aminoff 1, 1Kaiser Permanente, Department of Pediatrics, Oakland, 2Kaiser Permanente Northern California, Division of Research, Oakland, 3Kaiser Permanente, Department of Graduate Medical Education, Oakland

    Background/Purpose: Hydroxychloroquine (HCQ), a medication used to treat Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE) and Sjogren’s Syndrome (SS), reduces disease flare-ups, organ damage,…
  • Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting

    Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center

    Ohoud AlAhmed1, Amanda Way 2, Shoghik akoghlanian 2, Fatima Barbar-Smiley 2, Stephanie Lemle 2, Darby MacDonald 2, Kelly Wise 2, Stacy Ardoin 2 and Vidya Sivaraman 3, 1Nationwide Children's Hospital, Columbu, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Nationwide Children's Hospital and The Ohio State University, Columbus, OH

    Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
  • Abstract Number: 1891 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis

    Priyanka Iyer 1, Yubo Gao 2, Saket Girotra 2, Jeffrey Curtis 3, Mary Vaughan-Sarrazin 4 and Namrata Singh4, 1University of Iowa, Iowa City, IA, 2University of Iowa Hospitals and Clinics, Iowa city, IA, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Iowa, Iowa City

    Background/Purpose: Hydroxychloroquine (HCQ) has known immunomodulatory effects and mechanistic actions that may provide cardioprotective effects. To date, cardiovascular (CV) outcomes in elderly patients receiving HCQ…
  • Abstract Number: 2291 • 2019 ACR/ARP Annual Meeting

    Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus

    Stephen Balevic1, Michael Cohen-wolkowiez 2, Amanda Eudy 3, Mara Becker 4, Laura Schanberg 5 and Megan Clowse 3, 1Duke University, Hillsborough, NC, 2Duke University, Durham, NC, 3Duke University, Durham, 4Duke Children's Hospital, Durham, NC, 5Duke University Medical Center, Durham, NC

    Background/Purpose: Pregnancies in women with systemic lupus erythematosus (SLE) often result in preterm birth. Active disease during pregnancy significantly increases the risks for these poor…
  • Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting

    Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis

    Risa Wakiya1, Kiyo Ueeda 2, Hiromi Shimada 2, Shusaku Nakashima 1, Mai Mahmoud Fahmy Mansour 1, Mikiya Kato 1, Taichi Miyagi 1, Tomohiro Kameda 1 and Hiroaki Dobashi 2, 1Kagawa University, Kagawa, 2Kagawa University, Kagawa, Japan

    Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…
  • Abstract Number: 2529 • 2019 ACR/ARP Annual Meeting

    Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis

    Thibaut Naveau 1, Olivier Lichau 1, Thomas Barnetche 1, Thierry Schaeverbeke 1, Estibaliz Lazaro 2, Marie-Elise Truchetet 3 and Christophe Richez4, 1FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, 2FHU ACRONIM, Department of Internal Medecine, Centre Hospitalier Universitaire, Bordeaux, France, Pessac, France, 3FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France. Bordeaux University, CNRS 5164, 33000 Bordeaux, France, Bordeaux, France, 4Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France

    Background/Purpose: Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been used for years during pregnancy for multiple indications (malaria prevention, autoimmune disorders, etc.…). Recently, some countries face…
  • Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting

    Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States

    Thierry Dervieux1, Kelley Brady 1, Don Thomas 2, John Conklin 1, Eugene Fung 3, Claudia Ibarra 1 and Michelle Petri 4, 1Exagen, Vista, CA, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Arthritis & Osteoporosis Clinic, Waco, TX, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…
  • Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting

    Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)

    Sooyeon Kwon1, Jessica Farrell 2, Sarfaraz Hasni 3 and Shubhasree Banerjee 2, 1The Center For Rheumatology, Loudonville, NY, 2The Center for Rheumatology, LLC, Albany, NY, 3NIAMS, National Institutes of Health, Bethesda, MD

    Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE).  Studies suggest that a significant proportion of subjects are non-adherent to daily…
  • Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting

    Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment

    Naoto Yokogawa1, Masayuki Hashiguchi 2, Yoshiki Nagai 3, Kota Shimada 4, Shoji Sugii 1, Miho Oshima 5, Keigo Setoguchi 6 and Mikiko Shimizu 7, 1Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, 2Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan, 3Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, 4Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, 5Division of Rheumatology, Mitsui Memorial Hospital, Tokyo, Japan, 6Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, 7Department of Drug Metabolism and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Aomori University, Aomori, Japan

    Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology